中国批准了两种用于临床试验的实验性Covid-19疫苗

China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus that killed over 100,000 people worldwide, state media Xinhua reported on Tuesday.

据新华社周二报道，中国已批准两种实验性疫苗的早期人体试验，以对抗新型冠状病毒。该病毒在全世界造成10万人死亡。

The vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.

这些疫苗是由纳斯达克上市公司科兴生物科技(Sinovac Biotech)的北京子公司和国有企业中国医药集团(China National Pharmaceutical Group)的子公司武汉生物制品研究所(Wuhan Institute of Biological Products)联合开发的。

In March, China have the green-light for another clinical trial for a coronavirus vaccine candidate developed by military-backed China's Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio, shortly after US drug developer Moderna said it had begun human tests for their vaccine with the U.S. National Institutes of Health.

今年3月，在美国药物开发商 Moderna 宣布已经开始在美国国立卫生研究院进行人体试验之后不久，中国为由军方支持的中国军事医学科学院，和在香港上市的生物技术公司 CanSino Bio 开发的冠状病毒候选疫苗的另一项临床试验开了绿灯。

Vaccine needed to stop virus spread

世界需要疫苗来阻止病毒传播

The World Health Organization (WHO) said Monday that a safe and effective vaccine would be needed to fully halt the spread of Covid-19, which has killed more than 114,000 people worldwide.

世界卫生组织(WHO)周一表示，需要一种安全有效的疫苗，来完全阻止已导致全球11.4万人死亡的Covid-19的传播。

"Our global connectedness means the risk of re-introduction and resurgence of Covid-19 will continue," WHO Director-General Tedros Adhanom Ghebreyesus told a virtual briefing from Geneva, stressing that "ultimately, the development and delivery of a safe and effective vaccine will be needed to fully interrupt transmission."

世卫组织总干事Tedros Adhanom Ghebreyesus在日内瓦举行的一次虚拟新闻发布会上说:“我们的全球连通，意味着再次感染和复苏covid19的风险将继续存在。”他强调，“最终将需要开发和提供一种安全有效的疫苗，来完全阻断新型冠状病毒的传播。”